Small cell lung cancer: State of the art and future perspectives

Roger Stupp*, Christian Monnerat, Andrew T. Turrisi, Michael C. Perry, Serge Leyvraz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

142 Scopus citations


Small cell lung cancer accounts for less than 20% of all lung cancer. The management of this distinct tumor entity differs from the more common non-small cell lung cancer. Primary prevention of smoking exposure remains the most important public health measure. Although small cell lung is an exquisitely chemosensitive disease it remains ultimately fatal for the great majority of patients. Combination chemotherapy regimens have improved response rate and survival of the last three decades. The combination of cisplatin and etoposide has been considered the standard therapy for over a decade. More intensive triplet combination chemotherapy and high-dose chemotherapy have shown improved response rates and survival. Early concomitant and accelerated radiotherapy improves survival in limited stage disease. This review summarizes the current state of the art and future perspectives in detection, staging and standard therapy of small cell lung cancer. Particular emphasis is given to the importance of concomitant and accelerated radiotherapy and consideration of dose-intensive combination chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)105-117
Number of pages13
JournalLung Cancer
Issue number1
StatePublished - Jul 2004


  • Chemoradiotherapy
  • Conference report
  • High-dose chemotherapy
  • Hyperfractionated radiotherapy
  • New agents
  • Review
  • Small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Small cell lung cancer: State of the art and future perspectives'. Together they form a unique fingerprint.

Cite this